Antares pharma inc.

EWING, NJ, March 3, 2022 – Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today reported financial and operating results for the fourth quarter ended December 31, 2021 with record revenue of $48.7 million, net income of $32.7 million, or $0.19 per diluted earnings per share, and adjusted net ...Nov 4, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ... Aug 10, 2020 · Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ... Antares Pharma, Inc. (the “Company” or “Antares”) is an emerging specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company has numerous partnerships with pharmaceutical companies as well as multiple internal product …Antares Pharma announces FDA approval of Tlando™, an oral treatment for testosterone replacement therapy. News release. Antares Pharma Inc. Accessed March 29, 2022.

As previously disclosed, on February 28, 2014, Antares Pharma, Inc. (“Antares”) sued Medac Pharma, Inc. (“Medac”) and its foreign parent, medac GmbH, in the United States District Court for the District of Delaware alleging infringement. Antares is asserting four patents. On March 14, 2014, Antares filed a motion for preliminary injunction seeking to …

Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self. Pharmaceuticals. Ewing, NJ. 203 As of 2021 00000. 0.000 0000-00-00. 000000&0 00000. 000000. ore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, su. 000000000000000. Bolton, Canada. …

Antares Pharma Inc (NASDAQ:ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ:HALO) for $5.60 per share in cash, valuing ...Antares Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery ...Nov 10, 2022 · XYOSTED (testosterone enanthate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone ( 1 ). Safety and efficacy of XYOSTED in males less than 18 years old have not been established ( 1, 8.4 ). Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...

Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas.

Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...

Our multi-use, disposable pen injector complements our portfolio of single-use pressure assisted auto injector devices. The disposable pen injector device is designed to deliver drugs by injection through needles from multi-dose cartridges. Our disposable pen injector is designed for chronic conditions such as diabetes, which require daily ...Credit: Arek Socha from Pixabay. Halozyme Therapeutics has signed a definitive agreement for the acquisition of all of the outstanding shares of Antares Pharma in a deal valued at nearly $960m or $5.60 for each share, in cash. A speciality pharmaceutical firm, Antares focuses on developing pharmaceutical products and technologies to address ...As pet owners, we want to keep our furry friends safe and secure. Invisible Fence Inc. has been providing pet owners with innovative solutions to keep their pets out of harm’s way for over 40 years. With their advanced technology, Invisible...Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. Antares Pharma, Inc. (Amex:AIS) today announced an agreement with Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) to provide its needle-free injection system exclusively for use with a currently unnamed product in the U.S. Under the terms of the agreement, Teva will purchase all of its requirements for the injection system from …Jan 1, 2022 ... Pharmaceuticals, Inc. to make all required payments under the agreements; uncertainties regarding future FDA approval of. TLANDO®, market ...

Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas.Delaware . 1-32302 . 41-1350192 (State or other jurisdiction. of incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South ...Antares Pharma Inc. Follow. 3 results. BusinesscategoryHalozyme bolsters drug delivery business with $960 mln Antares deal April 13, 2022. MarketscategoryKroger ...Antares Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation SA Transcripts Thu, Nov. 05, 2020 Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q3 2020 Results - Earnings Call TranscriptCompany profile page for Antares Pharma Inc including stock price, company news, press releases, executives, board members, and contact informationDec 2, 2023 · Antares Pharma, Inc. (NASDAQ:ATRS) issued its quarterly earnings data on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to the consensus estimate of $48.52 million.

Scientific Publications. Curtis JR, Xie F, Zhang J, Chen L, Yun H, Beukelman T T, Ginsberg S, Schiff MH. “Patterns of Oral and Subcutaneous Methotrexate Use among Rheumatoid Arthritis Patients Enrolled in the U.S. Medicare Program. “ Poster presented at: The American College of Rheumatology, November 14-19, 2014: Boston, Ma. Halozyme Inc. is an Equal Employment Opportunity (EEO) employer. It is the policy of the Company to provide equal employment opportunities to all qualified applicants without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, age, protected veteran or disabled status, or genetic information.

On December 12, 2018, the Board of Directors (the “Board”) of Antares Pharma, Inc. (the “Company”) increased the size of the Board to eight members and, upon the recommendation of the Governance and Nominating Committee of the Board, appointed Peter Greenleaf to the Board as a Class I Director. Mr. Greenleaf’s term will expire at the …Dec 15, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ... Antares Pharma, Inc. (Amex:AIS) has elected Leonard S. Jacob, M.D., Ph.D. to the Company ' s Board of Directors.. Dr. Leonard Jacob joins Antares with over 29 years of pharmaceutical industry experience including having founded InKine Pharmaceutical Company Inc. in 1997 and served as Chairman and CEO from its …Antares Pharma is a leading company in the development and commercialization of self-administered injectable products. Learn more about its innovative portfolio, pipeline and financial performance in this investor presentation from January 2022. Revenue in 2021: $0.18 B ... According to Antares Pharma's latest financial reports the company's current revenue (TTM) is $0.18 B. In 2021 the company made a ...Minnetonka, Minnesota (763) 475-7700 12500 Whitewater Drive Minnetonka, MN 55343 USAAntares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...... Antares Pharma, Inc.'s and/or its affiliates (collectively “Antares”) or Antares co-branded websites. If you do not agree to the terms and conditions of ...Dec 31, 2021 · Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas.

EBITDA of $420 million to $440 million, representing growth of >30% over 2022. EBITDA excludes the impact of amortization costs related to the Antares Pharma acquisition.1 Non-GAAP diluted earnings per share of $2.65 to $2.75, representing growth of 20% over 20221.

About Antares Pharma . Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several …

Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself …Otrexup™ Methotrexate, Preservative Free 15 mg / 0.4 mL Injection Prefilled Auto-Injector 4 Devices Antares Pharma Inc 54436001504.3 Antares Pharma, Inc., Ewing, New Jersey, USA. 4 Men's Health Center, Miriam Hospital, Providence, Rhode Island, USA. PMID: 34510812 PMCID: PMC9293229 DOI: 10.1111/andr.13108 Abstract Background: To improve symptoms associated with testosterone deficiency, many testosterone therapies are available that aim to restore …Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Our multi-use, disposable pen injector complements our portfolio of single-use pressure assisted auto injector devices. The disposable pen injector device is designed to deliver drugs by injection through needles from multi-dose cartridges. Our disposable pen injector is designed for chronic conditions such as diabetes, which require daily ...Apr 13, 2022 · Antares Pharma Inc (NASDAQ:ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ:HALO) for $5.60 per share in cash, valuing ... Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of James E. Fickenscher to the position of Senior Vice President, Chief Financial Officer. Mr. Fickenscher has a diversified corporate background including more than 25 years of experience in the pharmaceutical industry. Most recently, Mr. Fickenscher served as …Antares Pharma, Inc. v. Medac Pharma Inc., 771 F.3d 1354, 1362 (Fed. Cir. 2014). As a result, the Court has previously held that the satisfaction of the requirements under 35 U.S.C. §251 is analogous to the requirements under 35 U.S.C. §112(a).About Antares Pharma . Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered …Antares Pharma Inc (Antares Pharma), a subsidiary of Halozyme Therapeutics Inc, is a specialty pharmaceutical company engaged in the development, …Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...

Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...May 24, 2022 ... ... Antares Pharma, Inc., a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical ...Scientific Publications. Curtis JR, Xie F, Zhang J, Chen L, Yun H, Beukelman T T, Ginsberg S, Schiff MH. “Patterns of Oral and Subcutaneous Methotrexate Use among Rheumatoid Arthritis Patients Enrolled in the U.S. Medicare Program. “ Poster presented at: The American College of Rheumatology, November 14-19, 2014: Boston, Ma. SAN DIEGO and EWING, N.J., April 13, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") and Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") today announced that the...Instagram:https://instagram. publicly listed wine companieswayfairstockbest art investment platformcheap option trading brokerage Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. vrssf stock forecast 2025sapphire pakistan Antares Pharma Inc. announced that Ferring Pharmaceuticals Inc. has received U.S. Food and Drug Administration approval of a name change enabling its newly acquired recombinant human growth hormone to be marketed in the U.S. as ZOMACTON (somatropin [rDNA origin]) for injection, and the needle-free delivery system to be …Antares Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery ... dollarttree Company profile page for Antares Pharma Inc including stock price, company news, press releases, executives, board members, and contact informationAll Drugs; Human Drugs; Animal Drugs ...Device Type: Auto-Injector: Dosage Type: Fixed: Injection Volume: 0.2-1.0ml Injection Type: SC or IM: Primary Container: 1.0ml long prefilled syringe